Central nervous system involvement in Burkitt lymphoma is a frequent complication, affecting less than 10% of patients with the endemic form, 10%–20% with the non-endemic form, and 20%–30% with the immunodeficiency-associated form. Here we discuss the distinct clinical features, diagnostic approach and chemotherapeutic treatment of three cases in our institution.